Tenax Therapeutics(TENX) - 2024 Q2 - Quarterly Results

EX-99.1 2 tenx_ex991.htm PRESS RELEASE EXHIBIT 99.1 Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 39 Investigative Sites Initiated In April, Hosted the KOL Event, "LEVEL Setting," Featuring Four Experts in Heart Failure Discussing the Unmet Medical Need in PH-HFpEF and Potential ...